Program
PROGRAM
July 11-14, 2020
session 1
Digital health & Biomarker
July 11 / 5.30 pm – 7 pm Beijing time
July 13 / 5.30 pm – 7 pm Athens time
State of the art of telemedicine trial results
J Cleland / UK
Using biomarkers in HF – update 2020
J Januzzi / USA
Managing HF patients in COVID-19 times
Y Zhang / China
Big data and AI approaches – what is on the horizon?
V Mahajan / India
session 2
Basics in HF: Clinical settings & treatments
July 11 / 8.30 pm – 10 pm Beijing time
July 13 / 8.30 pm – 10 pm Athens time
Treatment algorithm of HFrEF
J Ezekowitz / CAN
HFrEF vs HFmrEF vs HFpEF – similarities and differences
P Seferovic / SRB
Diagnostic approaches in HFpEF
C Lam / SING
Treatment approaches in HFpEF
S Solomon / USA
session 3
Valvular heart disease in HF
July 12 / 8.30 pm – 10 pm New York time
July 14 / 8.30 pm – 10 pm Athens time
State of art for imaging for diagnosis of valvular disease and assessment of risk
F Pinto / POR
Aortic valve disease
A Abizaid / BRA
Tricuspid disease
H Sievert / GER
Mitral valve disease
W Abraham / USA
session 4
State of the art management of chronic HF
July 11 / 5.30 pm – 7 pm Athens time
July 13 / 5.30 pm – 7 pm New York time
RAASi/ARNi, MRAs and beta blockers
F Zannad / FRAN
SGLT2 inhibitors
M Packer / USA
Vericiguat, the new data
B Pieske / GER
Managing anticoagulation in HF
G Rosano / ITA
session 5
Co-morbidities in HF (part 1)
July 12 / 5.30 pm – 7 pm Athens time
July 14 / 8.30 pm – 10 pm Beijing time
Diabetes in HF
J McMurray / UK
Atrial Fibrillation
J Atherton / AUS
Managing obesity and cachexia
M Abdelhamid / EGY
Sleep Apnea
M Boehm / GER
session 6
Co-morbidities in HF (part 2)
July 12 / 8.30 pm – 10 pm Athens time
July 14 / 5.30 pm – 7 pm Beijing time
CKD
C Yancy / USA
Hyperkalemia
J Butler / USA
ID with and without anaemia
P Ponikowski / POL
Exercise and managing frailty
S Makita / JAP
session 7
Update on acute HF
July 11 / 5.30 pm – 7 pm New York time
July 13 / 5.30 pm – 7 pm Beijing time
Management of AHF – State of the art
G Filippatos / GR
Post MI acute heart failure
A Hernandez / USA
Inflammatory cardiomyopathy and viral myocarditis
B Bozkurt / USA
Cardiogenic shock
– TBC –
session 8
Update on advanced HF, assist devices and heart transplantation
July 11 / 8.30 pm – 10 pm New York time
July 13 / 8.30 pm – 10 pm Beijing time
Patient with very poor prognosis and very low EF
DJ Choi / Korea
Mechanical circulatory support (MCS)
F Bader / UAE
Heart transplantation vs destination LVAD
L Stevenson / USA
Organising cardiac surgery and interventional care for HF in Covid times
M Metra / ITA
session 9
Difficult problems in HF
July 12 / 5.30 pm – 7 pm Beijing time
July 14 / 8.30 pm – 10 pm New York time
The patient with low blood pressure and poor renal function with acute HF
S Matskeplishvili / RUS
Elderly patient with mid-range EF and suspicion of amyloid
S Zieroth / CAN
Causes and management of heart failure in low resource settings
K Sliwa / SA
The patient with cancer and cardio-toxic chemotherapy
A Lyon / UK
session 10
New drugs and devices for HF therapy
July 12 / 8.30 pm – 10 pm Beijing time
July 14 / 5.30 pm – 7 pm New York time
Omecamtiv Mecarbil for chronic HF
J Teerlink / USA
Devices for functional MR beyond Mitraclip
S von Bardeleben / GER
Devices for baroreflex stimulation
A Coats / AUS
More on new drugs and devices on the horizon
S Anker / GER
session 11
Clinical trial update – part 1
July 11 / 8.30 pm – 10 pm Athens time
July 13 / 8.30 pm – 10 pm New York time
(new submissions)
session 12
Clinical trial update – part 2
July 12 / 5.30 pm – 7 pm New York time
July 14 / 5.30 pm – 7 pm Athens time
(new submissions)
Organized by
PROGRAM e-SPACE
